OBT at a glance
Pioneering an Innovative Approach for the Development of First-in-Class Cancer Therapies
Oxford BioTherapeutics is a clinical-stage oncology company, developing first-in-class antibody-based therapies to improve patient outcomes. Our proprietary, proteomic target discovery platform, OGAP®-Verify, specialises in identifying novel membrane-based protein targets.
This platform supports the development of antibody-drug conjugates (ADCs), chimeric antigen receptors (CAR-Ts), immuno-oncology antibodies (IOs), radiopharmaceutical and bispecific therapeutic modalities.
We continuously enhance our OGAP®-Verify database to accurately represent patient tumours and the tumour microenvironment. Our fully integrated discovery and development capabilities span from target identification to IND-enabling studies.
View our Pipeline
OBT’s mission is to become a key player in the ADC and T-cell engagers (TCE) field, with a reputation for innovation, scientific excellence, and commitment to improving patient outcomes and bringing much-needed therapies to patients worldwide
Our Team
Our success at Oxford BioTherapeutics is driven by a team that expertly combines scientific rigour with medical expertise
Stephen Blance, PhD CPA EPA
Director of Intellectual Property, Oxford
Stephen has over twenty years’ experience in intellectual property in the biotech field. Prior to joining OBT in 2014, Stephen worked in private practice at some of the largest UK patent and trademark firms gaining a broad range of experience in worldwide patent prosecution, providing freedom to operate opinions and European opposition procedures. Since joining OBT Stephen has been responsible for directing OBT’s global patent strategy and in providing general legal advice to senior management.
Investors
Oxford BioTherapeutics is Supported by a Syndicate of Leading Specialist Investors
A major portion of the investment into our ADC, IO, CAR-T and bispecific pipeline comes from strategic alliances with leading companies in the oncology field.
